{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2026,6,9]],"date-time":"2026-06-09T06:51:17Z","timestamp":1780987877878,"version":"3.54.1"},"reference-count":18,"publisher":"Oxford University Press (OUP)","issue":"7","license":[{"start":{"date-parts":[[2022,4,30]],"date-time":"2022-04-30T00:00:00Z","timestamp":1651276800000},"content-version":"vor","delay-in-days":0,"URL":"https:\/\/academic.oup.com\/journals\/pages\/open_access\/funder_policies\/chorus\/standard_publication_model"}],"funder":[{"DOI":"10.13039\/100000060","name":"NIAID","doi-asserted-by":"publisher","id":[{"id":"10.13039\/100000060","id-type":"DOI","asserted-by":"publisher"}]},{"DOI":"10.13039\/100000002","name":"NIH","doi-asserted-by":"publisher","award":["UM1AI104681"],"award-info":[{"award-number":["UM1AI104681"]}],"id":[{"id":"10.13039\/100000002","id-type":"DOI","asserted-by":"publisher"}]}],"content-domain":{"domain":[],"crossmark-restriction":false},"short-container-title":[],"published-print":{"date-parts":[[2022,6,29]]},"abstract":"<jats:title>Abstract<\/jats:title>\n               <jats:sec>\n                  <jats:title>Objectives<\/jats:title>\n                  <jats:p>Dalbavancin is a lipoglycopeptide with a long half-life, making it a promising treatment for infections requiring prolonged therapy, such as complicated Staphylococcus aureus bacteraemia. Free drug concentration is a critical consideration with prolonged treatment, since free concentration\u2013time profiles may best correlate with therapeutic effect. In support of future clinical trials, we aimed to develop a reliable and reproducible assay for measuring free dalbavancin concentrations.<\/jats:p>\n               <\/jats:sec>\n               <jats:sec>\n                  <jats:title>Methods<\/jats:title>\n                  <jats:p>The ultracentrifugation technique was used to determine free dalbavancin concentrations in plasma at two concentrations (50 and 200\u2005mg\/L) in duplicate. Centrifuge tubes and pipette tips were treated for 24\u2005h before use with Tween 80 to assess adsorption. Dalbavancin concentrations were analysed from the plasma samples (total) and middle layer samples (free) by LC\/MS\/MS with isotopically labelled internal standard. Warfarin served as a positive control with known high protein binding.<\/jats:p>\n               <\/jats:sec>\n               <jats:sec>\n                  <jats:title>Results<\/jats:title>\n                  <jats:p>Measurement of free dalbavancin was sensitive to adsorption onto plastic. Treatment of tubes and pipette tips with \u22652% Tween 80 effectively prevented drug loss during protein binding experiments. By the ultracentrifugation method, dalbavancin\u2019s protein binding was estimated to be approximately 99%.<\/jats:p>\n               <\/jats:sec>\n               <jats:sec>\n                  <jats:title>Conclusions<\/jats:title>\n                  <jats:p>Dalbavancin has very high protein binding. Given dalbavancin\u2019s high protein binding, accurate measurement of free dalbavancin concentrations should be a key consideration in future exposure\u2013response studies, especially clinical trials. Future investigations should confirm if the active fraction is best predicted by the free or total fraction.<\/jats:p>\n               <\/jats:sec>","DOI":"10.1093\/jac\/dkac131","type":"journal-article","created":{"date-parts":[[2022,4,14]],"date-time":"2022-04-14T11:13:13Z","timestamp":1649934793000},"page":"1899-1902","source":"Crossref","is-referenced-by-count":15,"title":["Determination of plasma protein binding of dalbavancin"],"prefix":"10.1093","volume":"77","author":[{"given":"Nicholas A","family":"Turner","sequence":"first","affiliation":[{"name":"Division of Infectious Diseases, Duke University School of Medicine , Durham, NC , USA"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Allan","family":"Xu","sequence":"additional","affiliation":[{"name":"Keystone Bioanalytical , North Wales, PA , USA"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Smitha","family":"Zaharoff","sequence":"additional","affiliation":[{"name":"Duke Clinical Research Institute , Durham, NC , USA"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Thomas L","family":"Holland","sequence":"additional","affiliation":[{"name":"Division of Infectious Diseases, Duke University School of Medicine , Durham, NC , USA"},{"name":"Duke Clinical Research Institute , Durham, NC , USA"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"ORCID":"https:\/\/orcid.org\/0000-0002-4730-0655","authenticated-orcid":false,"given":"Thomas P","family":"Lodise","sequence":"additional","affiliation":[{"name":"Albany College of Pharmacy and Health Sciences , Albany, NY , USA"}],"role":[{"vocabulary":"crossref","role":"author"}]}],"member":"286","published-online":{"date-parts":[[2022,4,30]]},"reference":[{"key":"2022110403593078800_dkac131-B1","doi-asserted-by":"crossref","first-page":"2067","DOI":"10.1161\/CIRCULATIONAHA.119.044913","article-title":"Incidence, microbiology, and outcomes in patients hospitalized with infective endocarditis","volume":"141","author":"Shah","year":"2020","journal-title":"Circulation"},{"key":"2022110403593078800_dkac131-B2","doi-asserted-by":"crossref","first-page":"e130","DOI":"10.1086\/648442","article-title":"Temporal trends in the incidence of Staphylococcus aureus bacteremia in Olmsted County, Minnesota, 1998 to 2005: a population-based study","volume":"49","author":"El Atrouni","year":"2009","journal-title":"Clin Infect Dis"},{"key":"2022110403593078800_dkac131-B3","doi-asserted-by":"crossref","first-page":"362","DOI":"10.1128\/CMR.05022-11","article-title":"Predictors of mortality in Staphylococcus aureus bacteremia","volume":"25","author":"van Hal","year":"2012","journal-title":"Clin Microbiol Rev"},{"key":"2022110403593078800_dkac131-B4","doi-asserted-by":"crossref","first-page":"1330","DOI":"10.1001\/jama.2014.9743","article-title":"Clinical management of Staphylococcus aureus bacteremia: a review","volume":"312","author":"Holland","year":"2014","journal-title":"JAMA"},{"key":"2022110403593078800_dkac131-B5","doi-asserted-by":"crossref","first-page":"7833","DOI":"10.1128\/AAC.01717-15","article-title":"Impact of glycopeptide resistance in Staphylococcus aureus on the dalbavancin in vivo pharmacodynamic target","volume":"59","author":"Lepak","year":"2015","journal-title":"Antimicrob Agents Chemother"},{"key":"2022110403593078800_dkac131-B6","doi-asserted-by":"crossref","first-page":"e01024-19","DOI":"10.1128\/AAC.01024-19","article-title":"Epithelial lining fluid and plasma concentrations of dalbavancin in healthy adults after a single 1,500-milligram infusion","volume":"63","author":"Rappo","year":"2019","journal-title":"Antimicrob Agents Chemother"},{"key":"2022110403593078800_dkac131-B7","doi-asserted-by":"crossref","first-page":"1849","DOI":"10.1128\/AAC.04550-14","article-title":"Extended-duration dosing and distribution of dalbavancin into bone and articular tissue","volume":"59","author":"Dunne","year":"2015","journal-title":"Antimicrob Agents Chemother"},{"key":"2022110403593078800_dkac131-B8","doi-asserted-by":"crossref","first-page":"274","DOI":"10.1128\/CMR.00092-12","article-title":"Importance of relating efficacy measures to unbound drug concentrations for anti-infective agents","volume":"26","author":"Gonzalez","year":"2013","journal-title":"Clin Microbiol Rev"},{"key":"2022110403593078800_dkac131-B9","doi-asserted-by":"crossref","first-page":"3442","DOI":"10.1016\/j.xphs.2017.09.005","article-title":"Industry perspective on contemporary protein-binding methodologies: considerations for regulatory drug-drug interaction and related guidelines on highly bound drugs","volume":"106","author":"Di","year":"2017","journal-title":"J Pharm Sci"},{"key":"2022110403593078800_dkac131-B10","doi-asserted-by":"crossref","first-page":"1633","DOI":"10.1128\/AAC.01264-06","article-title":"In vivo pharmacodynamic activity of the glycopeptide dalbavancin","volume":"51","author":"Andes","year":"2007","journal-title":"Antimicrob Agents Chemother"},{"key":"2022110403593078800_dkac131-B11","doi-asserted-by":"crossref","first-page":"179","DOI":"10.1093\/jac\/44.2.179","article-title":"In-vitro and in-vivo antibacterial activity of BI 397, a new semi-synthetic glycopeptide antibiotic","volume":"44","author":"Candiani","year":"1999","journal-title":"J Antimicrob Chemother"},{"key":"2022110403593078800_dkac131-B12","article-title":"Clinical Review: NDA 21883, Dalvance","author":"Iarikov"},{"key":"2022110403593078800_dkac131-B13","doi-asserted-by":"crossref","first-page":"673","DOI":"10.4155\/bio.13.338","article-title":"Bioanalysis for plasma protein binding studies in drug discovery and drug development: views and recommendations of the European Bioanalysis Forum","volume":"6","author":"Buscher","year":"2014","journal-title":"Bioanalysis"},{"key":"2022110403593078800_dkac131-B14","doi-asserted-by":"crossref","first-page":"21","DOI":"10.1002\/cpdd.695","article-title":"Dalbavancin population pharmacokinetic modeling and target attainment analysis","volume":"9","author":"Carrothers","year":"2020","journal-title":"Clin Pharmacol Drug Dev"},{"key":"2022110403593078800_dkac131-B15","article-title":"Package Insert: Warfarin"},{"key":"2022110403593078800_dkac131-B16","volume-title":"Protein Binding and the Antimicrobial Effects: Methods for the Determination of Protein Binding","author":"Criag","year":"1996"},{"key":"2022110403593078800_dkac131-B17","doi-asserted-by":"crossref","first-page":"2498","DOI":"10.1002\/jps.22452","article-title":"Validation of 96-well equilibrium dialysis with non-radiolabeled drug for definitive measurement of protein binding and application to clinical development of highly-bound drugs","volume":"100","author":"Zamek-Gliszczynski","year":"2011","journal-title":"J Pharm Sci"},{"key":"2022110403593078800_dkac131-B18","doi-asserted-by":"crossref","first-page":"1","DOI":"10.1007\/s40262-012-0018-5","article-title":"The clinical relevance of plasma protein binding changes","volume":"52","author":"Roberts","year":"2013","journal-title":"Clin Pharmacokinet"}],"container-title":["Journal of Antimicrobial Chemotherapy"],"original-title":[],"language":"en","link":[{"URL":"https:\/\/academic.oup.com\/jac\/article-pdf\/77\/7\/1899\/46783419\/dkac131.pdf","content-type":"application\/pdf","content-version":"vor","intended-application":"syndication"},{"URL":"https:\/\/academic.oup.com\/jac\/article-pdf\/77\/7\/1899\/46783419\/dkac131.pdf","content-type":"unspecified","content-version":"vor","intended-application":"similarity-checking"}],"deposited":{"date-parts":[[2022,11,4]],"date-time":"2022-11-04T03:59:52Z","timestamp":1667534392000},"score":1,"resource":{"primary":{"URL":"https:\/\/academic.oup.com\/jac\/article\/77\/7\/1899\/6576321"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2022,4,30]]},"references-count":18,"journal-issue":{"issue":"7","published-online":{"date-parts":[[2022,4,30]]},"published-print":{"date-parts":[[2022,6,29]]}},"URL":"https:\/\/doi.org\/10.1093\/jac\/dkac131","relation":{},"ISSN":["0305-7453","1460-2091"],"issn-type":[{"value":"0305-7453","type":"print"},{"value":"1460-2091","type":"electronic"}],"subject":[],"published-other":{"date-parts":[[2022,7,1]]},"published":{"date-parts":[[2022,4,30]]}}}